Immunotherapy for operable liver cancer before surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial studies durvalumab and tremelimumab (immunotherapy medicines) in people with resectable early or intermediate-stage liver cancer (HCC). It aims to see how well these medicines work before/around the time of surgery, and whether they can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign consent, and you’re over 18 years old
- Your liver cancer (HCC) is proven by biopsy, and it can be surgically removed
- You must agree to provide a biopsy sample before starting treatment
- Your general health is good (ECOG 0 or 1) and your liver is working well (Child-Pugh 5–6; ALBI grade 1)
- Your blood and organ tests are within required ranges (blood counts, kidney function, bilirubin, and liver enzymes)
- If you have hepatitis B, you must be on antiviral treatment with controlled virus levels; if you have hepatitis C, it must be managed per clinic plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs, tremelimumab and durvalumab, for people with advanced liver cancer (HCC) who have moderate cirrhosis (Child-Pugh B). The goal is to see if this treatment can shrink tumors or slow cancer growth.
This Phase 2 trial tests three medicines together (durvalumab, tremelimumab, and bevacizumab) to treat non-surgical (non-resectable) liver cancer. It may help shrink tumors and slow disease progression by boosting the immune system and blocking tumor blood supply.
This trial tests a combination of treatments before and after surgery for liver cancer that can be removed. The goal is to see if adding targeted therapy and immunotherapy can reduce the risk of cancer coming back.
This trial tests whether giving pembrolizumab (an immune therapy) and lenvatinib (a targeted pill) before planned liver surgery can improve outcomes for people with certain types of operable hepatocellular carcinoma (HCC). It’s meant for tumors that can be removed with curative intent, but still carry a risk of coming back.
This trial compares an immune “checkpoint” medicine to a targeted cancer medicine in people with advanced liver cancer who have hepatitis B in the blood. It aims to lower hepatitis B surface antigen (HBsAg) levels and see which approach works better and is safest.
This study tests whether adding two immunotherapy drugs (durvalumab and tremelimumab) plus radiation before surgery works better than radiation alone before surgery for people with resectable liver cancer. It's for those with a single tumor (or a few small nearby spots) that hasn't spread.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.